Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension

被引：0
作者：
Z. L. Zhang
E. Y. Liao
W. B. Xia
H. Lin
Q. Cheng
L. Wang
Y. Q. Hao
D. C. Chen
H. Tang
Y. De Peng
L. You
L. He
Z. H. Hu
C. L. Song
F. Wei
J. Wang
L. Zhang
A. C. Santora
机构：
[1] Shanghai Jiaotong University,Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Disease, The Sixth People’s Hospital
[2] Central South University,The Second Xiangya Hospital
[3] Peking Union Medical College Hospital,West China Hospital, West China School of Medicine
[4] Nanjing Drum Tower Hospital,Beijing Friendship Hospital
[5] Huadong Hospital Affiliated to Fudan University,Global Medical Affairs
[6] Tianjin Hospital,undefined
[7] Shanghai Ninth People’s Hospital,undefined
[8] Sichuan University,undefined
[9] Capital Medical University,undefined
[10] Shanghai First People’s Hospital,undefined
[11] Beijing Jishuitan Hospital,undefined
[12] Peking University People’s Hospital,undefined
[13] Peking University Third Hospital,undefined
[14] Merck Sharp & Dohme China,undefined
[15] Merck Research Laboratories,undefined
来源：
Osteoporosis International | 2015年 / 26卷
关键词：
Alendronate; Calcitriol; China; Postmenopausal osteoporosis; Vitamin D;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2365 / 2374
页数：9
相关论文
共 200 条
[1]  
Wang Y(2009)Osteoporosis in China Osteoporos Int 20 1651-1662
[2]  
Tao Y(2007)Prevalence and impact of vitamin D insufficiency in southern Chinese adults Ann Nutr Metab 51 59-64
[3]  
Hyman ME(2013)A glimpse of vitamin D status in Mainland China Nutrition 29 953-957
[4]  
Li J(2015)High prevalence of vitamin D deficiency among middle-aged and elderly individuals in northwestern China: its relationship to osteoporosis and lifestyle factors Bone 71 1-6
[5]  
Chen Y(2009)The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis J Bone Miner Metab 27 471-478
[6]  
Wat WZ(1985)Comparative analysis of two rates Stat Med 4 213-226
[7]  
Leung JY(1995)Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437-1443
[8]  
Tam S(1999)Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group Osteoporos Int 9 461-468
[9]  
Kung AW(2000)Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group Aging (Milano) 12 1-12
[10]  
Zhang W(2005)Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141-151
12345678910